AR029335A1 - Composicion para el tratamiento de trastornos de las secreciones externas, exceptuandose la disminucion del flujo lacrimal - Google Patents
Composicion para el tratamiento de trastornos de las secreciones externas, exceptuandose la disminucion del flujo lacrimalInfo
- Publication number
- AR029335A1 AR029335A1 ARP000100686A ARP000100686A AR029335A1 AR 029335 A1 AR029335 A1 AR 029335A1 AR P000100686 A ARP000100686 A AR P000100686A AR P000100686 A ARP000100686 A AR P000100686A AR 029335 A1 AR029335 A1 AR 029335A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- treatment
- dry
- composition
- external secretions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se revela una composicion para el tratamiento de trastornos de las secreciones externas, con excepcion de la disminucion del flujo lacrimal, que comprende, como componente activo, un inhibidor de la aldosa reductasa. La composicion es efectiva en , al menos uno a de las enfermedades seleccionadas de las siguientes: la disminucion del flujo salival (hiposalivacion) y el síndrome de boca seca. El inhibidor de la aldosa reductasa es preferentemente un compuesto de formula (1) en la cual A y B son, independientemente, alquileno inferior, X, Y y Z son, independientemente, halogenos, o sus sales farmacologicamente aceptables. También se describe el método para el tratamiento de los trastornos de las secreciones externas con dichos inhibidores de la aldosa reductasa y el uso de dichos compuestos para el tratamiento de los trastornos mencionados. Algunas de las enfermedades resultantes de los trastornos de las secreciones externas son: sequedad de varias partes del cuerpo, como el denominado "síndrome de boca seca" (xerostomía), "síndrome de nariz seca" (xeromicteria), "piel seca" (xeroderma), "síndrome de vagina seca"(síntoma de sequedad vaginal) y pancreatitis cronica, gastritis cronica y bronquitis cronica debida a al disminucion de la secrecion externa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12072599P | 1999-02-18 | 1999-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029335A1 true AR029335A1 (es) | 2003-06-25 |
Family
ID=22392173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100686A AR029335A1 (es) | 1999-02-18 | 2000-02-17 | Composicion para el tratamiento de trastornos de las secreciones externas, exceptuandose la disminucion del flujo lacrimal |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6339088B1 (es) |
| EP (1) | EP1073666A1 (es) |
| JP (1) | JP2003516309A (es) |
| AR (1) | AR029335A1 (es) |
| AU (1) | AU2462400A (es) |
| BR (1) | BR0005010A (es) |
| CA (1) | CA2328877A1 (es) |
| IL (1) | IL139071A0 (es) |
| MX (1) | MXPA00010193A (es) |
| NO (1) | NO20005216D0 (es) |
| WO (1) | WO2000048447A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555540B1 (en) * | 1999-06-30 | 2003-04-29 | Pfizer Inc | Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| JP2002265375A (ja) * | 2001-03-13 | 2002-09-18 | Inabata Koryo Kk | 唾液分泌促進剤及びこれを含有した食品組成物並びに口腔用組成物 |
| US20040047919A1 (en) * | 2002-06-13 | 2004-03-11 | Board Of Regents, The University Of Texas System | Methods and compositions involving aldose reductase inhibitors |
| US20110150974A1 (en) * | 2004-08-06 | 2011-06-23 | Daiichi Pharmaceutical Co., Ltd. | Agent For Oral Mucosal Administration |
| US20110092566A1 (en) * | 2004-11-19 | 2011-04-21 | Srivastava Satish K | Treatment of cancer with aldose reductase inhibitors |
| AU2008230949B2 (en) | 2007-03-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibitors |
| US20090270490A1 (en) * | 2008-04-24 | 2009-10-29 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibition |
| ITUB20152695A1 (it) * | 2015-07-31 | 2017-01-31 | Metis Healthcare S R L | Composizione per l'aumento delle secrezioni umorali |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8524663D0 (en) | 1985-10-07 | 1985-11-13 | Fujisawa Pharmaceutical Co | Quinazoline derivatives |
| US4931440A (en) | 1987-07-29 | 1990-06-05 | Fujisawa Pharmaceutical Company, Ltd. | Uricosuric composition |
| JP2621460B2 (ja) | 1988-02-29 | 1997-06-18 | 藤沢薬品工業株式会社 | 利尿または降圧剤 |
| WO2000001676A1 (en) | 1998-07-02 | 2000-01-13 | Neurosearch A/S | Potassium channel blocking agents |
| WO2000043015A1 (fr) * | 1999-01-25 | 2000-07-27 | Fujisawa Pharmaceutical Co., Ltd. | Gouttes ophtalmologiques |
-
2000
- 2000-02-15 EP EP00902961A patent/EP1073666A1/en not_active Withdrawn
- 2000-02-15 MX MXPA00010193A patent/MXPA00010193A/es unknown
- 2000-02-15 US US09/673,563 patent/US6339088B1/en not_active Expired - Fee Related
- 2000-02-15 AU AU24624/00A patent/AU2462400A/en not_active Abandoned
- 2000-02-15 JP JP2000599253A patent/JP2003516309A/ja active Pending
- 2000-02-15 BR BR0005010-5A patent/BR0005010A/pt not_active Application Discontinuation
- 2000-02-15 WO PCT/JP2000/000810 patent/WO2000048447A2/en not_active Application Discontinuation
- 2000-02-15 CA CA002328877A patent/CA2328877A1/en not_active Abandoned
- 2000-02-15 IL IL13907100A patent/IL139071A0/xx unknown
- 2000-02-17 AR ARP000100686A patent/AR029335A1/es unknown
- 2000-10-17 NO NO20005216A patent/NO20005216D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2328877A1 (en) | 2000-08-24 |
| WO2000048447A3 (en) | 2001-01-25 |
| JP2003516309A (ja) | 2003-05-13 |
| EP1073666A1 (en) | 2001-02-07 |
| IL139071A0 (en) | 2001-11-25 |
| US6339088B1 (en) | 2002-01-15 |
| BR0005010A (pt) | 2002-03-19 |
| WO2000048447A2 (en) | 2000-08-24 |
| MXPA00010193A (es) | 2002-04-17 |
| NO20005216D0 (no) | 2000-10-17 |
| AU2462400A (en) | 2000-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200500293A (es) | Derivados de prostaglandinas | |
| TR200201244T2 (tr) | Göz kurumasının iyileştirilmesi için Lipoksin A4 ve analogları | |
| MA28279A1 (fr) | Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2 | |
| BR0310047A (pt) | Análogos de 8-azaprostaglandina como agentes para diminuição de pressão intra-ocular | |
| NO20000841L (no) | N-Aroylfenylalanin-derivater | |
| CO5050288A1 (es) | Derivados de 1,4-oxazolina y de 1,3-tiazolina, procedimiento y su utilizacion como agentes plaguicidas | |
| BR0208192A (pt) | Derivados espirotricìclicos e seu uso como inibidores da fosfodiesterase-7. | |
| AR029335A1 (es) | Composicion para el tratamiento de trastornos de las secreciones externas, exceptuandose la disminucion del flujo lacrimal | |
| TR199800436A2 (xx) | Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�. | |
| PE20011314A1 (es) | DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA | |
| AR035637A1 (es) | Betamimeticos de larga accion, procedimiento para su preparacion y su empleo como medicamentos | |
| BR0007527A (pt) | Fenilfenantridinas com atividade inibitória depde-iv | |
| AR049262A1 (es) | Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias | |
| DK1200426T3 (da) | Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner | |
| HRP20020404B1 (en) | Solutions containing epinastine | |
| BR0209317A (pt) | Composições incluindo tensoativos com base em vitamina e métodos para usar as mesmas | |
| BR0209327A (pt) | Composição para tratamento de constipação induzida por drogas | |
| AR046728A1 (es) | Antagonistas de factor de transcripcion de la forma corta de c-maf para el tratamiento del glaucoma | |
| AR042733A1 (es) | Derivados de piridinas utilizados como inhibidores del mecanismo de intercambio na+/ca2+ | |
| NO20043115L (no) | Substituerte diketopiperaziner som oksytocin antagonister | |
| ES2164465T3 (es) | Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal. | |
| DK1395263T3 (da) | 3, 7 eller 3 og 7 thia- eller oxaprostansyrederivater som midler til at sænke intraokulært tryk | |
| AR018272A1 (es) | Una composicion oftalmica para el tratamiento de las lesiones de la cornea causadas por diabetes y/o para el tratamiento de la estesia de la corneadeteriorada y el uso del ingrediente activo de dicha composicion para la preparacion de dicha composicion oftalmica. | |
| UY25888A1 (es) | Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratorias | |
| UY26847A1 (es) | Derivados de la pirrolidina |